Learning Objectives
Upon completion of this activity, participants should be able to:
- Recount 48-week clinical trial data from phase III studies of etravirine, maraviroc, and raltegravir
- Describe goals of therapy for multidrug-resistant treatment-experienced patients
- Explain challenges in treating aging HIV-infected patients
- Discuss new insights into the adverse consequences of antiretroviral treatment interruptions
- Summarize the findings of recent research that sought to identify host proteins that play important roles in the HIV life cycle
CCO Stay Tuned provides the latest information from esteemed faculty in a modern media format. Complete the CME posttest and evaluation after reviewing the presentation.